You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. ARCHER- An Extremely Fast Medical Radiation Dose Computing Software

    SBC: VIRTUAL PHANTOMS INC            Topic: NIBIB

    DESCRIPTION provided by applicant The goal of this project is to develop a commercial software package for rapid Monte Carlo based dose computation in imaging and radiation therapy The product takes advantage of a desktop parallel computer equipped with emerging hardware originally developed gaming and high performance computing The project is motivated by the fact that the market is ripe for ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. ARCHER- An Extremely Fast Medical Radiation Dose Computing Software

    SBC: VIRTUAL PHANTOMS INC            Topic: NIBIB

    DESCRIPTIONprovided by applicantThe goal of this project is to develop a commercial software package for rapid Monte Carlo based dose computation in imaging and radiation therapyThe product takes advantage of a desktop parallel computer equipped with emerging hardware originally developed gaming and high performance computingThe project is motivated by the fact that the market is ripe for a produc ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  3. A simple and effective diagnostic test for gastrointestinal bleeding to improve patient outcomes

    SBC: CUMBERLAND PHARMACEUTICALS, INC.            Topic: 300

    DESCRIPTION provided by applicant Problem Lower gastrointestinal bleeding is a significant medical problem in the United States accounting for more than hospital admissions and tens of billions of dollars of healthcare spending annually It is common for bleeding from a single site to stop and restart multiple times The three modalities now used to diagnose and locate gastrointestina ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Cognitive Change Battery: An Assessment for Serial Administration

    SBC: COGMETRIC LLC            Topic: NIA

    ABSTRACT Detecting change in neuropsychological functioning over time is critical for proper diagnosis and management of many neurological psychiatric and psychological conditions It is well documented that most commonly used cognitive assessments produce significant retest effects such as practice and regression to the mean effects Retest effects can cause substantial changes in test score ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Controlled Release Polymer Structures for In Situ Chemical Oxidation of Contaminated Groundwater

    SBC: AXNANO LLC            Topic: NIEHS

    DESCRIPTION provided by applicant The EPA estimates that one out of every four Americans lives within three miles of a hazardous waste site Over brownfield sites are awaiting remediation and sites on the National Priorities List Potential Responsible Parties or the Superfund program are tasked with remediating these sites but insufficient funding and growing number of sites hav ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Developing a novel adjuvant system for therapeutic vaccines against lung cancer

    SBC: FasCure Therapeutics LLC            Topic: 102

    DESCRIPTION provided by applicant Therapeutics is focused on the development of adjuvant systems with desired immune activities for targeted indications The Companyandapos s immune stimulatory adjuvant platform builds on combinatorial use of immune agonists with distinct immune targets and mechanisms of action for the generation of therapeutic immune responses Critical to this platform techno ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Development and validation of therapy for mucopolysaccharidosis III

    SBC: Phoenix Nest Inc.            Topic: 105

    DESCRIPTION provided by applicant Sanfilippo syndrome mucopolysaccharidosis type III MPS III is a devastating neurodegenerative lysosomal storage disorder of childhood for which there is presently no cure or effective treatment available The fundamental cause of MPS III is an inherited mutation in one of the enzymes required to catabolize heparan sulfate HS a glycosaminoglycan which pla ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Development of An Integrated High Throughput Imaging and Image Analysis Platform for Muscle

    SBC: CytoInformatics LLC            Topic: NIA

    DESCRIPTION provided by applicant There is growing awareness that weakness of muscle is a significant biomedical health issue associated with many different chronic diseases and aging There are a variety of different diseases that affect muscle including muscular dystrophy fibromyalgia cerebral palsy amyotrophic lateral sclerosis and myasthenia gravis each of which carries its own uniqu ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a novel platform to enhance intracellular bioavailability of antisense morpholino oligomers

    SBC: NAJIT TECHNOLOGIES INC            Topic: NIAID

    DESCRIPTION provided by applicant Peptide conjugated phosphorodiamidate morpholino oligomers PPMO are single stranded nucleic acid analogs able to modulate gene expression through steric blocking of complementary RNA PPMO are composed of two components an antisense morpholino oligomer cargo covalently conjugated to a cell penetrating delivery peptide PPMO are completely nuclease resistant ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjects

    SBC: VIROGENOMICS BIODEVELOPMENT INC            Topic: NIAID

    DESCRIPTION provided by applicant Our laboratory discovered and is developing partial p MHC class II constructs pMHC as a possible immunotherapy for multiple sclerosis MS pMHC containing the extracellular domains of the MS risk factor HLA DR linked covalently to the encephalitogenic peptide of myelin oligodendrocyte glycoprotein pDR MOG can reverse CNS inflammation and ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government